From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.
Saved in:
| Title: | From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. |
|---|---|
| Authors: | Meyer JM; Department of Psychiatry, University of California, San Diego, San Diego, CA, United States., Kramer K; Bristol Myers Squibb, Princeton, NJ, United States., Vuocolo S; Bristol Myers Squibb, Princeton, NJ, United States., Kaul I; Bristol Myers Squibb, Princeton, NJ, United States., Miller AC; Bristol Myers Squibb, Princeton, NJ, United States. |
| Source: | The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2025 Apr 11; Vol. 28 (4). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9815893 Publication Model: Print Cited Medium: Internet ISSN: 1469-5111 (Electronic) Linking ISSN: 14611457 NLM ISO Abbreviation: Int J Neuropsychopharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1469-5111 |
|---|---|
| DOI: | 10.1093/ijnp/pyaf015 |
